Stock Events

Stock Events

Nykode Therapeutics AS 

$0.38
53
+$0.07+22.58% Monday 20:00

Statistics

Day High
0.31
Day Low
0.31
52W High
0.38
52W Low
0.16
Volume
10,000
Avg. Volume
237
Mkt Cap
124.09M
P/E Ratio
-
Dividend Yield
25.77%
Dividend
0.1

Upcoming

28
MAY
Dividend Ex
Estimated
 
12
JUN
Dividend Payment
Estimated
 
28
MAY 27
Dividend Ex
Estimated
 
11
JUN 27
Dividend Payment
Estimated
 
29
MAY 28
Dividend Ex
Estimated
 

Dividends

25.77%Dividend Yield
Jun 25
$0.1
Jun 25
$0.1
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
-50.16%

Earnings

27MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.53
-0.41
-0.3
-0.19
Expected EPS
N/A
Actual EPS
N/A

Financials

-447.3%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
17.36MRevenue
-77.64MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VACBF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a leader in mRNA technology, directly competing in the vaccine and therapeutic space similar to Nykode's focus on novel immunotherapies.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes in the development of novel mRNA vaccines and therapeutics, similar to Nykode's approach in immunotherapy.
Novavax
NVAX
Mkt Cap1.36B
Novavax is involved in the development of vaccines for infectious diseases, competing with Nykode's vaccine development efforts.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and markets vaccines and therapeutics, including mRNA vaccines, competing in the same space as Nykode.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline focuses on vaccines and therapeutics, including efforts in the immunotherapy space, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson develops vaccines and therapeutics, including efforts in immunotherapy, competing with Nykode's product pipeline.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is involved in the development of vaccines and therapeutics, including immunotherapy treatments, competing with Nykode.
Arcturus Therapeutics
ARCT
Mkt Cap270.73M
Arcturus Therapeutics is engaged in mRNA vaccine and therapeutic development, competing in the same technological space as Nykode.
Incyte
INCY
Mkt Cap18.35B
Incyte focuses on the discovery, development, and commercialization of therapeutics, including immunotherapies, making it a competitor in the same field as Nykode.

About

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Show more...
CEO
Mr. Michael Thyring Engsig
Country
NO
ISIN
NO0010714785

Listings

F
DE
5VB.F
OTC Link
US
VACBF
OL
NO
NYKD.OL

0 Comments

Share your thoughts

FAQ

What is Nykode Therapeutics AS stock price today?▼
The current price of VACBF is $0.38 USD — it has increased by +22.58% in the past 24 hours. Watch Nykode Therapeutics AS stock price performance more closely on the chart.
What is Nykode Therapeutics AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nykode Therapeutics AS stocks are traded under the ticker VACBF.
What is Nykode Therapeutics AS market cap?▼
Today Nykode Therapeutics AS has the market capitalization of 124.09M
When is the next Nykode Therapeutics AS earnings date?▼
Nykode Therapeutics AS is going to release the next earnings report on May 27, 2026.
What is Nykode Therapeutics AS revenue for the last year?▼
Nykode Therapeutics AS revenue for the last year amounts to 17.36M USD.
What is Nykode Therapeutics AS net income for the last year?▼
VACBF net income for the last year is -77.64M USD.
Does Nykode Therapeutics AS pay dividends?▼
Yes, VACBF dividends are paid annual. The last dividend per share was 0.1 USD. As of today, Dividend Yield (FWD)% is 25.77%.
In which sector is Nykode Therapeutics AS located?▼
Nykode Therapeutics AS operates in the Health Care sector.
When did Nykode Therapeutics AS complete a stock split?▼
The last stock split for Nykode Therapeutics AS was on July 07, 2020 with a ratio of 5:1.
Where is Nykode Therapeutics AS headquartered?▼
Nykode Therapeutics AS is headquartered in Oslo, NO.